All In Biotech

Drug Trial Radar · NCT00523965

Combination Therapy in Indian Visceral Leishmaniasis

A Randomised, Open-label, Parallel-group, Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens (Co-administration), of AmBisome, Paromomycin and Miltefosine in Visceral Leishmaniasis (VL)

Last checked: Nov 19, 2026Latest source record: May 26, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 624 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

624

Planned (sponsor's estimate)

Start

Sep 2007

Primary completion

Aug 2009

Study completion Feb 2010

Sponsor

Lead sponsor
Banaras Hindu UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Drugs for Neglected Diseases; Rajendra Memorial Research Institute of Medical Sciences
First posted
Sep 3, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rationale The overall objective of this trial is to identify a safe and effective combination, (co-administration) short course treatment for the treatment of VL which could be easily deployed in a control programme. The hypothesis is that the combination treatment is as effective or better than the 5 mg/kg single dose of AmBisome and will reduce the risk of parasite resistance occurring. Safety and tolerability should be such that the combination can be easily deployed. Objective The specific primary and secondary objectives are as follows: Primary objective: To identify a short course combination treatment regimen which is at least as effective as a single dose of AmBisome 5mg/kg Secondary objective: To compare safety and tolerability of the various treatments measured by vital signs, blood biochemistry, (renal and liver function tests) haematology, spontaneous and elicited adverse event reporting Primary Endpoint: The primary efficacy endpoint variable is parasitological clearance 2 weeks after start of treatment with no relapse during follow up and no clinical signs or symptoms of VL at 6 months post treatment. Parasitology is only carried out at any time during follow-up or at six months post treatment if there are signs or symptoms of VL infection.

Conditions

  • Leishmaniasis, Visceral

Interventions

  • amphotericin B deoxycholateDrug

    Amphotericin B deoxycholate 1 mg/kg on alternate days for 15 infusions

  • Liposomal Amphotericin B with MiltefosineDrug

    Liposomal Amphotericin B 5 mg Miltefosine 50 mg twice daily if patient weighs equal to or \> 25 kg Miltefosine 50 mg once daily if patient weighs \<25 mg

  • Liposomal Amphotericin B and Paromomycin SulfateDrug

    AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11

  • miltefosine + Paromomycin sulfateDrug

    oral miltefosine 50mg once daily (\< 25 kg body weight) or twice daily ( \> 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Final cure at six month follow upTime frame: 18 months
  2. Cure at six month follow upTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kala-azar Medical Research Center

    Muzaffarpur, Bihar, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.